GRACEcast
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Visit Show Website http://cancerGRACE.org/Recently Aired
-
HD
Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer (audio)
Dr. Colin Weekes, pancreatic cancer specialist from the University of ...
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for post-operative (adjuvant) therapy for resectable pancreatic cancer.
-
HD
Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer (video)
Dr. Colin Weekes, pancreatic cancer specialist from the University of ...
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for pre-operative (neoadjuvant) therapy for resectable pancreatic cancer.
-
HD
Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer (audio)
Dr. Colin Weekes, pancreatic cancer specialist from the University of ...
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer.
-
HD
Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer (video)
Dr. Colin Weekes, pancreatic cancer specialist from the University of ...
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer.
-
HD
Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer (audio)
Dr. Colin Weekes, pancreatic cancer specialist from the University of ...
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer.
-
HD
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (video)
Dr. Edward Garon, David Geffen School of Medicine at UCLA, ...
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
-
HD
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)
Dr. Edward Garon, David Geffen School of Medicine at UCLA, ...
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
-
HD
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (video)
Dr. Edward Garon, David Geffen School of Medicine at UCLA, ...
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.
-
HD
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)
Dr. Edward Garon, David Geffen School of Medicine at UCLA, ...
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.
-
HD
ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (video)
Dr. Edward Garon, David Geffen School of Medicine at UCLA, ...
Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.
